Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

Table 1 Quality assessment of all included studies

Study	Selection	Comparability	Exposure	Randomization	Masking	Accountability of all patients	Quality (score)
Randomized controlled trial
Sadighi et al[18], 2006				**	**	*	5
Roth et al[10], 2007				**	*	*	4
Gao et al[11], 2010				**	**	*	5
Babu et al[9], 2017				*	*	*	3
Retrospective study
Abbasi et al[19], 2010	***	**	*				6
Kilickap et al[8], 2011	***	**	**				7
Teker et al[12], 2014	****	**	***				9

Table 2 Characteristics of the included studies

Ref.	Yr	Intervention and control	Samples	ORR (%)	OS	PFS	Design	Quality (score)
Sadighi et al[18]	2006	DCF: D 60 mg/m2, d1, C 60 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	44	42.0	-	-	RCT	5/5
		ECF: E 60mg/m2, d1, C 60 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	42	37.0	-	-
Roth et al[10]	2007	DCF: D 85mg/m2, d1, C 75 mg/m2, d1, F 300 mg/m2/d, d1-14 (21)	41	36.6	10.4	4.6	RCT	4/5
		ECF: E 50 mg/m2, d1, C 60 mg/m2, d1, F 200 mg/m2/d, d1-21 (21)	40	25.0	8.3	4.9
Abbasi et al[19]	2010	DCF: D 75mg/m2, d1, C 75 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	30	56.3	10.81	6.81	RS	6/9
		ECF: E 50 mg/m2, d1, C 60 mg/m2, d1, F 200 mg/m2/d, d1-21 (21)	113	31.3	8.06	5.13
Gao et al[11]	2010	DCF: D 60 mg/m2, d1, C 25 mg/m2, d1-3, F 1000 mg/m2, 46 h, pumping (21)	32	59.3	-	-	RCT	5/5
		ECF: E 50 mg/m2, d1, C 25 mg/m2, d1-3, F 1000 mg/m2, 46 h, pumping (21)	32	32.6	-	-
Kilickap et al[8]	2011	DCF: D 75 mg/m2, d1, C 75 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	40	40.0	9.6	5.8	RS	7/9
		ECF: E 50 mg/m2, d1, C 60 mg/m2, d1, F 250 mg/m2/d, d1-21 (21)	40	30.0	10.1	4.4
Teker et al[12]	2014	DCF: D 50-75 mg/m2, d1, C 50-75 mg/m2, d1, F 500-750 mg/m2/d, d1-5 (21)	42	26.2	11	6.0	RS	9/9
		ECF: E 50 mg/m2, d1, C 60 mg/m2, d1, F 200 mg/m2/d, d1-21 (21)	44	29.5	10	6.0
Babu et al[9]	2017	DCF: D 75 mg/m2, d1, C 60 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	28	46.4	12.5	7.5	RCT	3/5
		ECF: E 50 mg/m2, d1, C 60 mg/m2, d1, F 750 mg/m2/d, d1-5 (21)	30	26.7	9.4	5.8

ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; ECF: Epirubicin, cisplatin, and 5-fluorouracil; DCF: Docetaxel, cisplatin, and 5-fluorouracil; RCT: Randomized controlled trial.